With a masters degree in clinical medicine, he is a Deputy Chief Physician in oncology surgery and an intermediate specialist in general surgery and plastic surgery. He is a registered doctor for the drug donation projects of the China Cancer Foundation, China Charity Federation, and China Primary Healthcare Foundation.

She was awarded the "Outstanding Individual" title by the hospital in 2017; her department was honored as the "Advanced Team" in 2017; she received the "Most Cooperative Individual" award in 2019; her department was awarded the "Most Cooperative Department" title; she was recognized as an "Outstanding Employee" by the First Investment Group system in 2019; she was honored as the "Most Beautiful Physician" by the hospital in 2020; she won the Excellence Award in the CSCO Breast Cancer Diagnosis and Treatment Guidelines Seminar and Standardized Treatment Competition in 2018; and she received the Best Presence Award in the South China Region of the Roche Breast Cancer Standardized Diagnosis and Treatment Competition in 2019.

She specializes in the diagnosis and treatment of breast cancer, particularly in minimally invasive and breast plastic surgery techniques, and has extensive experience in early diagnosis and comprehensive management of breast cancer.

Breast tumor, GCP drug clinical trial.

I. Member of the Second Youth Council of the Chinese Anti-Cancer Association

II. Member of the 10th Committee of the Breast Cancer Professional Committee of the Chinese Anti-Cancer Association

III. Member of the Breast Health Popularization Group of the Third Committee of the Medical Science Popularization Branch of the Chinese Medical Doctor Association

IV. Vice Chairman of the Breast Cancer Youth Committee of the Hainan Provincial Anti-Cancer Association

V. Secretary-General of the Breast Tumor Special Committee of the Hainan Provincial Cancer Prevention and Control Association

I. "Outstanding Individual" of Hainan Cancer Hospital - 2017

II. "Most Cooperative Individual" at Hainan Cancer Hospital - 2019

III. "Outstanding Employee" of the Group - 2019

IV. "The Most Beautiful Physician" of Hainan Cancer Hospital on Chinese Physicians Day - 2020

I. CircPDSS1 promotes the proliferation, invasion, migration, and epithelial-mesenchymal transition (EMT) of breast cancer cells via regulation of the miR-320c/CKAP5 axis. Cancer Cell Int. 2022 Jul 28; 22 (1): 238.

II. RNA SOX21-AS1 regulates the progression of triple-negative breast cancer through regulation of the miR-520a-5p/ORMDL3 axis. J Cell Biochem. 2020;10.1002/jcb.29674.

III. Effectiveness of prophylactic application of negative pressure wound therapy in stopping surgical site wound problems for closed incisions in breast cancer surgery: A meta-analysis. Int Wound J. 2023 Feb; 20 (2): 241-250.

IV. Superselective arterial embolization with drug-loaded microspheres for the treatment of unresectable breast cancer. Gland Surg. 2019; 8 (6): 740-747.

V. Construction of tandem affinity tag LOX protein lentiviral expression vector and its expression in breast cancer cells. Modern Biomedical Progress, 2015, 15(29):5613-5616.

VI. Verification of the interaction between LOX and XRCC5 in human breast cancer cells using immunoprecipitation technology. Journal of Guangxi Medical University, 2016, 33(01):6-9.

VII. Application of tandem affinity purification technology in studying intracellular interacting proteins.

VIII. Medical Review, 2014, 20(7): 1153-1156.